Clinical Trials Logo

Malignant Primary Brain Tumors clinical trials

View clinical trials related to Malignant Primary Brain Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04396717 Recruiting - Clinical trials for Brain Metastases, Adult

Safety Study of Pritumumab in Brain Cancer

Start date: March 18, 2021
Phase: Phase 1
Study type: Interventional

Pritumumab is a human IgG1 kappa antibody that binds to a malignant tumor associated antigen, ecto domain-vimentin (EDV) which is expressed in a variety of tumor cells. Pritumumab was shown to have relatively high reactivity with brain cancer cell lines, while no reactivity was demonstrated with normal neurons, astrocytes or fetal cerebral cells. Pritumumab has notable antibody-dependent cellular cytotoxicity (ADCC), brain tumor penetration and antitumor activity in nude mouse human xenograft models. Primary Objectives - To determine the safety and/or tolerability and the recommended Phase 2 dose (RP2D) of escalating, intravenously (IV) administered Pritumumab doses in patients with recurrent gliomas or with brain metastases. Secondary Objectives - To determine pharmacokinetics and pharmacodynamics of Pritumumab - To identify preliminary signals of anti-tumor response to Pritumumab - To explore disease-related, patient-reported outcomes